Rats are the preferred animal models for the study of human diseases (or pathologies), such as obesity, ageing, cancer, diabetes, transplantation and cardiovascular research. Rat models show more physiological similarities to humans than mice. Due to their larger size, surgical intervention can be performed and monitored more easily than in mice.PolyGene is now proud to further expand its services to the development of transgenic rat models. For this goal, PolyGene joined forces with ImmunoGenes AG, one of the leaders in transgenic technology. This strategic collaboration combines PolyGenes' two decades of experience in animal model development and its use of sophisticated exclusive and novel inducible expression systems with the excellent track record of ImmunoGenes in the generation of transgenic animals in a variety of species, including prominently rats and rabbits.
ImmunoGenes is a biopharmaceutical company specialized in the generation of transgenic animals for the production of polyclonal and monoclonal antibodies. Using genetically modified animals in a patented process, sufficient quantities of antibodies can be harvested far faster than using standard techniques. ImmunoGenes AG is incorporated in Zug, Switzerland with a subsidiary in Budapest, Hungary. For further information, please see ImmunoGenes’ website (www.immunogenes.com).
